Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company ...

Being insulin-treated is one of the requirements for typical CGM devices like DexCom's G6 ... Its current forward price-to-earnings ratio is 44, while the average for the healthcare industry ...

DexCom recently launched Stelo CGM, its first over-the-counter glucose sensor targeting non-insulin using adults with Type 2 diabetes or prediabetes in the United States. This move expands DexCom ...

In a report released on December 17, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...

Abbott has announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the ...

Dexcom has become the first company to launch a generative AI-powered continuous glucose monitor. The San Diego healthcare ...

DexCom recently launched Stelo CGM, its first over-the-counter glucose sensor targeting non-insulin using adults with Type 2 diabetes or prediabetes in the United States. This move expands DexCom's ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

(NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI ...

Leach said Dexcom is also exploring how its generative AI platform can be used across its other CGM products, but the company is proceeding extra carefully since patients rely on them to prevent ...